4//SEC Filing
Waterhouse Alan 4
Accession 0001256928-09-000025
CIK 0001168335other
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 8:55 PM ET
Size
18.8 KB
Accession
0001256928-09-000025
Insider Transaction Report
Form 4
Waterhouse Alan
Corporate Vice President
Transactions
- Disposition to Issuer
Common Stock
2009-02-26$22.00/sh−1,606$35,332→ 0 total - Tax Payment
Common Stock
2009-02-25$22.01/sh−1,788$39,354→ 3,212 total - Award
Common Stock
2009-02-25+2,500→ 2,500 total - Tax Payment
Common Stock
2009-02-25$22.01/sh−894$19,677→ 1,606 total - Disposition to Issuer
Employee Stock Option (Right to Buy)
2009-02-26−20,000→ 0 totalExercise: $22.88From: 2009-02-25Exp: 2018-03-03→ Common Stock (20,000 underlying) - Award
Common Stock
2009-02-25+5,000→ 5,000 total - Disposition to Issuer
Common Stock
2009-02-26$22.00/sh−3,212$70,664→ 0 total - Disposition to Issuer
Employee Stock Option (Right to Buy)
2009-02-26−9,060→ 0 totalExercise: $22.94From: 2009-02-25Exp: 2018-05-29→ Common Stock (9,060 underlying)
Footnotes (4)
- [F1]The exempt restricted stock units (previously reported on Table II) vested in full and were settled for shares of Issuer Common Stock in accordance with the terms of the applicable equity plan. At the effective time of the merger (defined in the Agreement and Plan of Merger dated January 11, 2009, by and among Abbott Laboratories, Rainforest Acquisition Inc. and the Issuer ("Merger Agreement"), such shares were cancelled pursuant to the Merger Agreement in exchange for the right to receive cash payment of $22.00 per share in cash (without interest and subject to any required withholding taxes).
- [F2]Shares withheld in satisfaction of tax obligations attributable to the lapse of restrictions on stock award or in satisfaction of tax withholding attributable to vesting and settlement of restricted stock units.
- [F3]This previously reported exempt stock option, which was to have vested ratably over the first four years from the date of grant, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 8,205 shares of Abbott Laboratories common stock at an exercise price of $55.77 per share, determined pursuant to a formula set forth in the Merger Agreement.
- [F4]This previously reported exempt stock option, which was to have vested ratably over the first four years from the date of grant, will be exchanged for a fully vested stock option issued by Abbott Laboratories to purchase 3,717 shares of Abbott Laboratories common stock at an exercise price of $55.92 per share, determined pursuant to a formula set forth in the Merger Agreement.
Documents
Issuer
ABBOTT MEDICAL OPTICS INC
CIK 0001168335
Entity typeother
Related Parties
1- filerCIK 0001451628
Filing Metadata
- Form type
- 4
- Filed
- Feb 26, 7:00 PM ET
- Accepted
- Feb 27, 8:55 PM ET
- Size
- 18.8 KB